Volume 6, Issue 2 (5-2022)
EBHPME 2022, 6(2): 118-125 |
Back to browse issues page
Department of Health Management and Economics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , maryamdargahpour@gmail.com
Abstract: (993 Views)
Background: The most well-known classification of the cost of diseases is direct medical cost. The aim of this study is to investigate and analyze direct treatment costs of patients with Covid-19 by hospitals affiliated with Ilam University of Medical Sciences.
Methods: This was a descriptive-analytical, cross-sectional study performed retrospectively. The hospital expenditure information in Ilam province from March to October 2020 was used. Cost information related to all patients was collected and classified and reviewed using Excel 2016 software. The average direct treatment costs of hospitalized patients were also determined.
Results: The direct costs of treatment in hospitalized patients in Ilam were estimated at $ 2349272.094 (98669427959 billion Rials). The per capita direct medical costs were calculated to be $ 1228.056 (51578373 million Rials(. The largest share of the cost related to pharmaceutical services and the share of basic insurance was equal to $ 934.570 (39,252,109 million Rials).
Conclusion: Results of the study indicated that the treatment costs of patients entering Ilam province are high, and the highest cost concerns pharmaceutical services. Taking necessary measures to prevent and control the spread of coronary artery, using the most cost-effective drug interventions and reducing unnecessary hospital stays of patients can increase the efficiency of financial resources and reduce direct medical costs in Ilam province.
Methods: This was a descriptive-analytical, cross-sectional study performed retrospectively. The hospital expenditure information in Ilam province from March to October 2020 was used. Cost information related to all patients was collected and classified and reviewed using Excel 2016 software. The average direct treatment costs of hospitalized patients were also determined.
Results: The direct costs of treatment in hospitalized patients in Ilam were estimated at $ 2349272.094 (98669427959 billion Rials). The per capita direct medical costs were calculated to be $ 1228.056 (51578373 million Rials(. The largest share of the cost related to pharmaceutical services and the share of basic insurance was equal to $ 934.570 (39,252,109 million Rials).
Conclusion: Results of the study indicated that the treatment costs of patients entering Ilam province are high, and the highest cost concerns pharmaceutical services. Taking necessary measures to prevent and control the spread of coronary artery, using the most cost-effective drug interventions and reducing unnecessary hospital stays of patients can increase the efficiency of financial resources and reduce direct medical costs in Ilam province.
Type of Study: Applicable |
Subject:
Health Economics
Received: 2022/03/16 | Accepted: 2022/05/20 | Published: 2022/07/3
Received: 2022/03/16 | Accepted: 2022/05/20 | Published: 2022/07/3
References
1. 1. Lange S, Vollmer S. The effect of economic development on population health: A review of the empirical evidence. British Medical Bulletin. 2017; 121(1): 47-60. [DOI:10.1093/bmb/ldw052]
2. United Nations (UN). Shared responsibility, global solidarity: Responding to the socio-economic impacts of COVID-19. Available from URL: https:// unsdg.un.org/sites/default/files/ 2020-03/SG-Report-Socio-Economic-Impact-of-Covid19.pdf. Last Access: 21 May, 2020.
3. Arabi YM, Murthy S, Webb S. COVID-19: A novel Coronavirus and a novel challenge for critical care. Intensive Care Medicine. 2020; 46(5): 833-6. [DOI:10.1007/s00134-020-05955-1]
4. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, et al. Severe respiratory illness caused by a novel Coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro surveillance. 2012; 17(40): 20290. [DOI:10.2807/ese.17.40.20290-en]
5. Salinas-Escudero G, Carrillo-Vega MF, Granados-García V, Martínez-Valverde S, Toledano-Toledano F, Garduño-Espinosa J. A survival analysis of COVID-19 in the Mexican population. BMC Public Health. 2020; 20(1): 1-8. [DOI:10.1186/s12889-020-09721-2]
6. World Meters. Coronavirus Update (Live). Available from URL: https://www.worldometers. info/ coronavirus. Last Access: 30 May, 2021.
7. International Monetary Fund (IMF). World Economic Outlook, April 2020. Available from URL:https://www.imf.org/en/Publications/WEO/Issues/2020/04/14/weo-april. Last Access: 14 April, 2020.
8. Darab MG, Keshavarz Kh, Sadeghi E, Shahmohamadi J, Kavosi Z. The economic burden of Coronavirus disease 2019 (COVID-19): Evidence from Iran. BMC Health Services Research. 2021; 21(1): 132. [DOI:10.1186/s12913-021-06126-8]
9. Jayadevappa, R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of pocket and indirect costs of prostate cancer. The Prostate. 2010; 70(11): 1255-64. [DOI:10.1002/pros.21161]
10. Imani A, Ahmadipoor Sh, Janati A, Gholipoor K, Ghoddousinejad J. Analysis and estimation of the direct and indirect costs of breast cancer in women attending Shahid Ghazi clinic, Tabriz, 2013. Depiction of Health. 2019; 5(3): 13-9. [In Persian]
11. Raoofi A, Takian A, Sari AA, Olyaeemanesh A, Haghighi H, Aarabi M. COVID-19 pandemic and comparative health policy learning in Iran. Archives of Iranian Medicine (AIM). 2020; 23(4): 220-34. [DOI:10.34172/aim.2020.02]
12. Maleki S, Parvizian A, Alizadeh M, Ahmadi H. Evaluation of health indicators in the cities of Ilam. Journal of Geography and Environment Studies. 2017; 6(21): 75-90. [In Persian]
13. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson M-A, Byass P, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modeling study. The Lancet Global Health. 2020; 8(4): e497-e510. [DOI:10.1016/S2214-109X (19)30545-5]
14. The world Bank. Official exchange rate (LCU per US$, period average). Official exchange rate (LCU per US$, period average). Available from URL: https://data.worldbank.org/indicator/PA.NUS.FCRF. Last Access: 28 May, 2021.
15. Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund ShS, et al. The potential health care costs and resource use associated with COVID-19 in the United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health Affairs. 2020; 39(6): 927-35. [DOI:10.1377/hlthaff.2020.00426]
16. Mohanty SK, Dubey M, Mishra US, Sahoo U. Impact of COVID-19 attributable deaths on longevity, premature mortality and DALY: Estimates of USA, Italy, Sweden and Germany. MedRxiv. 2020; 1-21. [DOI:10.1101/2020.07.06.20147009]
17. Jin H, Wang H, Li X, Zheng W, Ye Sh, Zhang Sh, et al. Economic burden of COVID-19, China, January-March, 2020: A cost-of-illness study. Bulletin of the World Health Organization. 2021; 99(2): 112-24. [DOI:10.2471/BLT.20.267112]
18. Maher A, Jahanmehr N, Karimi F, Damiri S. An analysis of the Covid 19 crisis in Iran and the World, COVID- 19 and its effects on Iran's health economy. Tehran, Iran: Teymourzadeh Publication; 2020: 129. [In Persian]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |